Tenaya Therapeutics Inc(TNYA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TNYA Tenaya Therapeutics Inc

交易中 06-03 14:08:53 EDT

0.7851

-0.0049

-0.62%

最高0.8600	最低0.7603	成交量450.33万
今开0.8600	昨收0.7900	日振幅12.62%
总市值1.70亿	流通市值1.62亿	总股本2.17亿
成交额356.90万	换手率2.19%	流通股本2.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TNYA","market":"US","secType":"STK","nameCN":"Tenaya Therapeutics Inc","latestPrice":0.7851,"timestamp":1780510128927,"preClose":0.79,"halted":0,"volume":4503349,"delay":0,"changeRate":-0.006202531645569639,"floatShares":205841252,"shares":216505900,"eps":-0.461845,"marketStatus":"交易中","change":-0.0049,"latestTime":"06-03 14:08:53 EDT","open":0.86,"high":0.86,"low":0.7603,"amount":3568965.3280464,"amplitude":0.126203,"askPrice":0.7899,"askSize":100,"bidPrice":0.7801,"bidSize":39,"shortable":3,"etf":0,"ttmEps":-0.461845,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780516800000},"marketStatusCode":2,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":0.79,"preHourTrading":{"tag":"盘前","latestPrice":0.8749,"preClose":0.79,"latestTime":"09:29 EDT","volume":302514,"amount":255133.349778,"timestamp":1780493387514,"change":0.0849,"changeRate":0.107468,"amplitude":0.085949},"postHourTrading":{"tag":"盘后","latestPrice":0.8399,"preClose":0.79,"latestTime":"19:59 EDT","volume":309687,"amount":257224.149619,"timestamp":1780444788697,"change":0.0499,"changeRate":0.063165,"amplitude":0.082278},"volumeRatio":1.483627,"impliedVol":1.2009,"impliedVolPercentile":0.3108},"requestUrl":"/m/hq/s/TNYA/","defaultTab":"news","newsList":[{"id":"1117050360","title":"Tenaya Therapeutics：所有可评估患者在Tn-201治疗后，Mybpc3相关HCM均显示改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1117050360","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117050360?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:06","pubTimestamp":1780484799,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics公司宣布，在其候选疗法Tn-201的临床研究中，所有可评估的Mybpc3基因相关肥厚型心肌病患者均显示出病情改善。这一积极数据为治疗这一严重遗传性心脏病带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNYA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198463241","title":"Tenaya Therapeutics - 队列1获益持续长达两年；队列2显示更早改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1198463241","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198463241?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:03","pubTimestamp":1780484593,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics公司公布的最新数据显示，其疗法在两项患者队列中展现出积极且持久的临床效果。\n第一队列的患者获益得以持续长达两年之久，凸显了该疗法的长期潜力与稳定性。与此同时，第二队列的数据则传递出更为鼓舞人心的信号：患者表现出更早的临床改善。这一发现可能意味着该疗法在疾病进程的较早阶段介入，能带来更显著的治疗反应，为未来的应用策略提供了关键见解。\n两项结果共同指向了该疗法的积极前景，后续进展值得持续关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165666908","title":"Tenaya Therapeutics公布Mypeak™-1中期数据：Tn-201基因疗法治疗Mybpc3相关HCM显示心脏重构迹象与症状减轻","url":"https://stock-news.laohu8.com/highlight/detail?id=1165666908","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165666908?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:01","pubTimestamp":1780484483,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics公司公布了其Mypeak™-1研究的中期数据。数据显示，使用Tn-201基因疗法治疗与Mybpc3基因相关的肥厚型心肌病，已观察到持续的心脏重构迹象，并伴随患者症状的减轻。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178770965","title":"Tenaya Therapeutics将于2026年6月3日公布Tn-201治疗成人Mybpc3相关HCM的Mypeak™-1期1B/2期试验新中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1178770965","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178770965?lang=zh_cn&edition=full","pubTime":"2026-06-03 04:31","pubTimestamp":1780432282,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc  计划于2026年6月3日（星期三）公布其候选药物Tn-201在Mypeak-1 1B/2期临床试验中的新中期数据。该试验旨在评估Tn-201用于治疗成人MYBPC3基因相关肥厚型心肌病患者的疗效与安全性。肥厚型心肌病是一种以心肌异常增厚为特征的疾病，而MYBPC3基因突变是其常见的遗传病因之一。公司选择在年中公布这一批中期数据，或将为投资者评估其研发管线价值提供重要依据，并可能影响市场对该生物技术公司前景的判断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128772341","title":"Tenaya Therapeutics Inc - TN-401不良事件呈无症状性，可自行缓解或对治疗产生应答","url":"https://stock-news.laohu8.com/highlight/detail?id=1128772341","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128772341?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:04","pubTimestamp":1778839484,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc 公布的数据显示，其药物TN-401在临床试验中观察到的不良事件均为无症状性质，并且这些事件最终自行缓解或对相应的治疗干预产生了良好应答。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199972376","title":"Tenaya 公司 Tn-401 药物 Ridge™-1 1B/2 期临床试验队列 1 和 2 中期积极数据：为 PKP2 相关 ARVC 成人患者持续减轻心律失常负担","url":"https://stock-news.laohu8.com/highlight/detail?id=1199972376","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199972376?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:02","pubTimestamp":1778839361,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics 公司公布了其候选药物 Tn-401 在 Ridge™-1 1B/2 期临床试验中，针对 PKP2 基因相关致心律失常性右室心肌病成人患者的最新中期数据。来自队列 1 和队列 2 的初步结果显示，该疗法能够持续、显著地降低患者的心律失常负担。这一积极信号为后续研究奠定了重要基础，也增强了该创新疗法在治疗这一罕见且严重心脏病方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146995051","title":"Tenaya Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1146995051","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146995051?lang=zh_cn&edition=full","pubTime":"2026-03-12 04:05","pubTimestamp":1773259522,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc（简称：Tenaya Therapeutics）近日披露了其2025财年第四季度及全年度的财务报告，同时向市场同步了公司最新的业务动态。此次公布的信息涵盖了公司在财务表现和战略推进方面的关键进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177542029","title":"Tenaya Therapeutics与Alnylam Pharmaceuticals达成研究合作，共同探索心血管疾病治疗新靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1177542029","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177542029?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:36","pubTimestamp":1772717783,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc（简称Tenaya）已与Alnylam Pharmaceuticals（简称Alnylam）正式签署一项研究合作协议。双方将携手致力于识别并验证针对心血管疾病治疗的新型遗传靶点，旨在推动相关疗法研发取得突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","LU0109394709.USD","LU0320765992.SGD","LU0882574055.USD","BK4548","BK4585","TNYA","LU0889565916.HKD","BK4588","LU0114720955.EUR","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608203334","title":"Tenaya Therapeutics, Inc.盘中异动 股价大跌5.03%报0.856美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608203334","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608203334?lang=zh_cn&edition=full","pubTime":"2026-02-04 01:27","pubTimestamp":1770139665,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日01时27分，Tenaya Therapeutics, Inc.股票出现异动，股价快速跳水5.03%。Tenaya Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。Tenaya Therapeutics, Inc.公司简介：Tenaya Therapeutics Inc 是一家临床前阶段的生物技术公司，专注于发现、开发和提供治疗性疗法，解决心脏病的潜在驱动因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020401274597a4b736&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020401274597a4b736&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TNYA","LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145036007","title":"Tenaya Therapeutics预计2026年上半年公布Tn-401治疗PKP2相关ARVC的Ridge-1研究一年期队列1数据及早期队列2数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1145036007","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145036007?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:35","pubTimestamp":1767965725,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc宣布，针对PKP2相关致心律失常性右室心肌病（ARVC）的基因疗法Tn-401，其Ridge-1临床研究预计将于2026年上半年公布重要进展。届时将披露队列1患者接受治疗满一年的随访数据，同时公布队列2研究的早期结果。\n该时间规划凸显了公司对推进罕见心脏病创新疗法的承诺。Ridge-1研究数据的陆续出炉，将为评估Tn-401疗法的安全性与有效性提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198326862","title":"Tenaya Therapeutics宣布迅速解决并解除对Mypeak-1™ Tn-201基因疗法I期B/II期临床试验的临床监管","url":"https://stock-news.laohu8.com/highlight/detail?id=1198326862","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198326862?lang=zh_cn&edition=full","pubTime":"2025-12-12 05:02","pubTimestamp":1765486978,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics宣布迅速解决并解除对Mypeak-1™ Tn-201基因疗法I期B/II期临床试验的临床监管","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187787927","title":"Tenaya Therapeutics Inc：首两名患者在第八周表现出强大的转导能力和Pkp2蛋白水平的显著增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1187787927","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187787927?lang=zh_cn&edition=full","pubTime":"2025-12-12 05:02","pubTimestamp":1765486939,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc：首两名患者在第八周表现出强大的转导能力和Pkp2蛋白水平的显著增加","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175073936","title":"Tenaya Therapeutics Inc - 在两个患者中观察到显著的心律失常负担减少，随访超过六个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1175073936","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175073936?lang=zh_cn&edition=full","pubTime":"2025-12-12 05:02","pubTimestamp":1765486935,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc - 在两个患者中观察到显著的心律失常负担减少，随访超过六个月","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518789128","title":"Tenaya Therapeutics(TNYA.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为100万美元；每股收益为-0.28美元，前值为-0.40美元，预期值为-0.31美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789128","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518789128?lang=zh_cn&edition=full","pubTime":"2025-03-11 05:45","pubTimestamp":1741643101,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics(TNYA.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为100万美元；每股收益为-0.28美元，前值为-0.40美元，预期值为-0.31美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11054548643208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153575348","title":"Tenaya Therapeutics 2024年第四季度GAAP每股亏损$0.28，优于预期的$0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=1153575348","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153575348?lang=zh_cn&edition=full","pubTime":"2025-03-11 04:10","pubTimestamp":1741637435,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics报告季度每股亏损$0.28，优于分析师一致预期的$0.31，超出9.68%。与去年同期每股亏损$0.40相比，这一数据增长了30%。以上内容来自Benzinga Earnings专栏，原文如下：Tenaya $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 9.68 percent. This is a 30 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518719812","title":"Tenaya Therapeutics, Inc.股价飙升20.88% 市值涨1771.06万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518719812","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518719812?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613505,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Tenaya Therapeutics, Inc.股票出现波动，股价急速拉升20.88%。Tenaya Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.59%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Biodexa Pharmaceuticals Plc涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为1916.39%、394.22%、52.01%，振幅较大的相关个股有Xencor, Inc.、Seer, Inc.、珐博进，振幅分别为99.13%、98.72%、98.49%。Tenaya Therapeutics, Inc.公司简介：Tenaya Therapeutics Inc 是一家临床前阶段的生物技术公司，专注于发现、开发和提供治疗心脏病的潜在驱动因素的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213145abf2fc08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213145abf2fc08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TNYA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517366169","title":"Tenaya Therapeutics, Inc.盘中异动 早盘股价大涨5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517366169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517366169?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271506,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Tenaya Therapeutics, Inc.股票出现波动，股价快速拉升5.98%。Tenaya Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。其相关个股中，Plus Therapeutics, Inc.、Exicure, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为946.46%、104.14%、48.84%，振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Astria Therapeutics, Inc.，振幅分别为24.20%、13.05%、11.88%。Tenaya Therapeutics, Inc.公司简介：Tenaya Therapeutics Inc 是一家临床前阶段的生物技术公司，专注于发现、开发和提供治疗心脏病的潜在驱动因素的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223146abeb7788&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223146abeb7788&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","TNYA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517910524","title":"Tenaya Therapeutics, Inc.股价上涨17.16% 市值涨700.78万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517910524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517910524?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185025,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分，Tenaya Therapeutics, Inc.股票出现波动，股价大幅拉升17.16%。Tenaya Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为310.54%、251.30%、183.65%，振幅较大的相关个股有4D Molecular Therapeutics, Inc.、Plus Therapeutics, Inc.、Zura Bio Limited，振幅分别为8.56%、6.59%、5.61%。Tenaya Therapeutics, Inc.公司简介：Tenaya Therapeutics Inc 是一家临床前阶段的生物技术公司，专注于发现、开发和提供治疗心脏病的潜在驱动因素的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223026a260c6a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223026a260c6a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","BK4139","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516765668","title":"Tenaya Therapeutics, Inc.盘中异动 下午盘股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516765668","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516765668?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:01","pubTimestamp":1741032083,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时01分，Tenaya Therapeutics, Inc.股票出现波动，股价急速下跌5.21%。Tenaya Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4574.50%、211.64%、182.38%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Tenaya Therapeutics, Inc.公司简介：Tenaya Therapeutics Inc 是一家临床前阶段的生物技术公司，专注于发现、开发和提供治疗心脏病的潜在驱动因素的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040401239637f5c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040401239637f5c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TNYA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778971","title":"Tenaya Therapeutics, Inc.盘中异动 早盘急速下挫5.86%报1.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513778971?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:57","pubTimestamp":1740409072,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时57分，Tenaya Therapeutics, Inc.股票出现波动，股价急速下挫5.86%。Tenaya Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为147.60%、62.30%、25.08%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Tenaya Therapeutics, Inc.公司简介：Tenaya Therapeutics Inc 是一家临床前阶段的生物技术公司，专注于发现、开发和提供治疗心脏病的潜在驱动因素的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225752a2521ada&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225752a2521ada&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TNYA","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tenayatherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0102},{"period":"1month","weight":0.1193},{"period":"3month","weight":0.3588},{"period":"6month","weight":-0.4275},{"period":"1year","weight":0.7174},{"period":"ytd","weight":0.1103}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tenaya Therapeutics, Inc.于2016年8月在特拉华州注册成立。该公司是一家临床前阶段的生物技术公司，专注于发现、开发和提供治疗心脏病的潜在驱动因素的治疗方法。公司正在从三个不同但相互关联的产品平台推进产品候选：基因治疗、细胞再生和精准医疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.091688},{"month":2,"riseRate":0.2,"avgChangeRate":-0.006231},{"month":3,"riseRate":0.4,"avgChangeRate":-0.077091},{"month":4,"riseRate":0.2,"avgChangeRate":0.069395},{"month":5,"riseRate":0.4,"avgChangeRate":0.046898},{"month":6,"riseRate":0.2,"avgChangeRate":-0.074059},{"month":7,"riseRate":0.5,"avgChangeRate":-0.023292},{"month":8,"riseRate":0.4,"avgChangeRate":0.09529},{"month":9,"riseRate":0.4,"avgChangeRate":-0.101393},{"month":10,"riseRate":0.2,"avgChangeRate":-0.046678},{"month":11,"riseRate":0.4,"avgChangeRate":0.123533},{"month":12,"riseRate":0.2,"avgChangeRate":-0.128991}],"exchange":"NASDAQ","name":"Tenaya Therapeutics Inc","nameEN":"Tenaya Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tenaya Therapeutics Inc(TNYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tenaya Therapeutics Inc(TNYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tenaya Therapeutics Inc,TNYA,Tenaya Therapeutics Inc股票,Tenaya Therapeutics Inc股票老虎,Tenaya Therapeutics Inc股票老虎国际,Tenaya Therapeutics Inc行情,Tenaya Therapeutics Inc股票行情,Tenaya Therapeutics Inc股价,Tenaya Therapeutics Inc股市,Tenaya Therapeutics Inc股票价格,Tenaya Therapeutics Inc股票交易,Tenaya Therapeutics Inc股票购买,Tenaya Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tenaya Therapeutics Inc(TNYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tenaya Therapeutics Inc(TNYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}